Résumé :
|
[BDSP. Notice produite par INIST-CNRS 9AH9IR0x. Diffusion soumise à autorisation]. Enterolignans are biphenolic compounds that possess several biologic activities whereby they may influence carcinogenesis. The authors investigated the association between plasma enterolactone and enterodiol and colorectal cancer risk in a Dutch prospective study. Among more than 35,000 participants aged 20-59 years, 160 colorectal cancer cases were diagnosed after 7.5 years of follow-up (1987-2003). Cohort members who were frequency-matched to the cases on age, sex, and study center were selected as controls (n=387). Plasma enterodiol and enterolactone were not associated with risk of colorectal cancer after adjustment for known colorectal cancer risk factors (highest quartile vs. lowest : for enterodiol, odds ratio=1.11,95% confidence interval : 0.56,2.20 (p-trend=0.75) ; for enterolactone, odds ratio=1.70,95% confidence interval : 0.88,3.27 (p-trend=0.15)). However, sex (p-interaction=0.06) and body mass index (p-interaction
|